OABI OmniAb, Inc.

NASDAQ
$3.38

OmniAb, Inc. (OABI) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +42.6% since its last earnings release on August 6, 2026.

OmniAb, Inc. Beat Consensus Estimates, Raises Guidance
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.12)
Rev est $5.15M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.29

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About OmniAb, Inc.

OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.

Sector

Healthcare

Industry

Research Services

Held By 1 ETFs, by dollar flow